Castle Biosciences Reports Third Quarter 2026 Results
PR Newswire•05/11/2026•16:05 ET
0
Key Highlights
- ➤Q3 revenue $102.9 million, up 24% year over year
- ➤2026 revenue guidance raised to $385-395 million from $365-375 million
- ➤TissueCypher test report volume increased 47% year over year
- ➤Q3 net loss widened to $4.1 million from $0.5 million
- ➤Q3 Adjusted EBITDA rose to $12.7 million from $9.2 million
Expert Statements
Derek Maetzold, President and Chief Executive Officer of Castle Biosciences
“Our team delivered another strong quarter, reflecting consistent execution across our portfolio,”
Derek Maetzold, President and Chief Executive Officer of Castle Biosciences
“TissueCypher was a key contributor to our top-line performance, delivering 47% year-over-year growth in test report volume compared to the third quarter of 2025.”
Derek Maetzold, President and Chief Executive Officer of Castle Biosciences
“We generated $19.7 million in net cash provided by operating activities, reflecting our disciplined approach to expense management and operational efficiency while continuing to invest in strategic growth opportunities.”
Derek Maetzold, President and Chief Executive Officer of Castle Biosciences
“DecisionDx-Melanoma continues to serve as the foundation of our dermatologic testing franchise, with 5% year-over-year growth in test report volume through the first nine months of 2026 compared to the same period in 2025.”
Derek Maetzold, President and Chief Executive Officer of Castle Biosciences
“Alongside DecisionDx-Melanoma, AdvanceAD-Tx™ and DecisionDx®-SCC broaden the clinical value of our dermatologic portfolio and position us to support our medium- and long-term growth opportunities, and combined, our dermatology commercial team delivered 15,168 test reports in the third quarter.”
Derek Maetzold, President and Chief Executive Officer of Castle Biosciences
“Overall, our third-quarter results reflect the strength of our portfolio, consistent execution and continued progress toward our long-term growth objectives.”
Derek Maetzold, President and Chief Executive Officer of Castle Biosciences
“I want to thank the entire Castle team for their dedication, hard work and unwavering commitment to improving patient care.”
Castle Biosciences Reports Third Quarter 2026 Results PR Newswire
Delivered Q3 2026 revenue of $102.9 million, an increase of 24% over Q3 2025
Get started
Create a free account to read the full story.